Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG193 + IDE397 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG193 | AMG-193|AMG 193 | PRMT5 Inhibitor 21 | AMG193 inhibits protein arginine methyltransferase 5 (PRMT5), potentially leading to inhibition of tumor cell proliferation (NCI Drug Dictionary). | |
| IDE397 | IDE397 inhibits MAT2A inhibitor which may reduce synthesis of S-adenosyl-L-methionine (SAM), potentially leading to anti-tumor activity in MTAP-deficient cancers (Cancer Res 2021;81(13_Suppl):Abstract nr 1278). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05975073 | Phase Ib/II | AMG193 + IDE397 | A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | Active, not recruiting | USA | ESP | DNK | CAN | AUS | 2 |